• 1
    Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004; 364: 249256.
  • 2
    Solomon D, Schiffman M, Tarone R, The ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 293299.
  • 3
    Jones HW 3rd. Impact of the Bethesda System. Cancer. 1995; 76(10 Suppl ): 19141918.
  • 4
    Jones BA, Davey DD. Quality management in gynecologic cytology using inter-laboratory comparison. Arch Pathol Lab Med. 2000; 124: 672681.
  • 5
    Bohmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia Grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol. 2003; 189: 118120.
  • 6
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 1219.
  • 7
    Wright TC Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002; 287: 21202129.
  • 8
    The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000; 92: 397402.
  • 9
    Solomon D, Davey D, Kurman R, et al, Forum Group Members, Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 21142119.
  • 10
    de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995; 76: 10571062.
  • 11
    Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. “Touchdown” PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res. 1991; 19: 4008.
  • 12
    Evans MF, Adamson CS, Cooper K. Improved detection of human papillomavirus DNA in cervical and breast tissues by hot start, touchdown general primer PCR, and optimized sample DNA concentration [abstract]. Mod Pathol. 2004; 17: 1496A.
  • 13
    de Roda Husman AM, Snijders PJ, Stel HV, van den Brule AJ, Meijer CJ, Walboomers JM. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer. 1995; 72: 412417.
  • 14
    Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000; 87: 221227.
  • 15
    Munoz N, Bosch FX, de Sanjose S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518527.
  • 16
    Qureshi MN, Bolick DR, Zafar N, Pambuccian SE, McGlennen RC. To triage or not? A multi-institutional study examining prevalence of HPV high-risk types in LSIL cases [abstract 74A]. Mod Pathol. 2005; 18( Suppl 1): 330.
  • 17
    Konya J, Veress G, Juhasz A, et al. Additional human papillomavirus types detected by the Hybrid Capture tube test among samples from women with cytological and colposcopical atypia. J Clin Microbiol. 2000; 38: 408411.
  • 18
    Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol. 2002; 25( Suppl 3): S89S97.
  • 19
    United States Bureau of the Census. Vermont QuickLinks website. Available at URL: [accessed August 2005].
  • 20
    Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol. 1997; 35: 13041310.
  • 21
    Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 15001505.
  • 22
    Papillo JL, St. John TL, Stumler R, Riley ER, Ianni MS. Utility of Digene HPV triage significantly reduced with Bethesda 2001 ASC-US [abstract 10A]. Acta Cytol. 2003; 47: 841842.
  • 23
    Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004; 364: 16781683.
  • 24
    Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004; 91: 942953.
  • 25
    Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619631.
  • 26
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC, 1995.
  • 27
    Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000; 87: 221227.
  • 28
    Masumoto N, Fujii T, Ishikawa M, et al. Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women; study of 881 outpatients. Gynecol Oncol. 2004; 94: 509514.
  • 29
    Broker TR, Jin G, Croom-Rivers A, et al. Viral latency—the papillomavirus model. Dev Biol (Basel). 2001; 106: 443451.